systemic lupus erythematosus [SLE]/lupus nephritis [LN] research hub

The CALiPSO-1 Study: A Study of CNTY-101, a CD19-targeted CAR iNK Cell Product, in Participants with Refractory B cell-mediated Autoimmune Diseases

This study looks into a new treatment, CNTY-101, for serious autoimmune diseases like lupus, muscle inflammation, and a type of skin hardening. It's an early-stage study to see if this treatment is safe and how it works in people.